Pablo Corral Shares Insights on Remnant Cholesterol and Its Role in Atherosclerotic Cardiovascular Disease
Pablo Corral, Past President of Argentine Lipid Society, has shared a post on LinkedIn:
“A significant presence in atherosclerotic cardiovascular disease: Remnant cholesterol: A review
Remnant cholesterol: the overlooked driver of residual risk in ASCVD
Despite achieving LDL-C targets with statins and novel lipid-lowering therapies, patients remain exposed to substantial residual cardiovascular risk. Emerging evidence highlights remnant cholesterol (RC)—the cholesterol content of triglyceride-rich lipoproteins—as a causal factor in atherosclerosis.
Epidemiological, genetic, and mechanistic studies consistently show that elevated RC predicts major adverse cardiovascular events, independently of LDL-C. Mendelian randomization confirms a causal role, while clinical data suggest that RC promotes endothelial dysfunction, inflammation, and thrombosis.
Although lifestyle interventions remain essential, pharmacologic strategies—including statins, fibrates, PCSK9 inhibitors, and novel gene-targeted therapies—can reduce RC levels. However, standardized measurement and clear therapeutic targets are still lacking.
RC should be recognized as a priority marker in cardiovascular prevention, guiding future strategies to reduce residual risk in high-risk populations”
Title: A significant presence in atherosclerotic cardiovascular disease: Remnant cholesterol: A review
Authors: Li Wang, Qingmei Zhang, Zhiyang Wu, Xiwei Huang
Read the full article here.
Stay informed with Hemostasis Today.
-
Jul 12, 2026, 08:50Where the Hemophilia Community Comes Together at ISTH 2026 – EAHAD
-
Jul 12, 2026, 08:2210 Posts Not To Miss from ISTH 2026, Part 1
-
Jul 12, 2026, 07:58Brian O Mahony: Could NXT-007 Minimize the Need for Perioperative FVIII
-
Jul 12, 2026, 07:50Shayan Mohammadmoradi: Connecting the Next Generation of Hemostasis Researchers at ISTH 2026
-
Jul 12, 2026, 07:42Alexandra Yakusheva: ThrombInnov Debuts at ISTH 2026 with a Focus on Translational Research
-
Jul 12, 2026, 07:34Wolfgang Miesbach: ISTH 2026 Explores the Next Generation of APS Diagnostics
-
Jul 12, 2026, 07:28Sara Zalghout: ISTH 2026 Highlights Progress in Thromboinflammation Research
-
Jul 12, 2026, 07:13Ekaterina Balaian: Finding Healing Through Art at ISTH 2026
-
Jul 12, 2026, 06:59Maaike Sybil Jongen: Flow Cytometry for Platelet Phenotyping at ISTH 2026